Frontline Immunotherapy Combo Setbacks Strike NSCLC – OncLive
OncLive |
Frontline Immunotherapy Combo Setbacks Strike NSCLC
OncLive Bristol-Myers Squibb (BMS) and AstraZeneca have each announced separate delays in the development of PD-1 and CTLA-4 inhibitor combinations as first-line therapies for patients with advanced or metastatic non–small cell lung cancer (NSCLC), … |
